These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34904684)

  • 21. The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
    Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
    Adv Ther; 2023 May; 40(5):2493-2508. PubMed ID: 36930429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
    Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
    J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
    J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
    Teeple A; Fitzgerald T
    J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database.
    Fitzgerald T; Teeple A; Slaton T; Kozma CM
    J Drugs Dermatol; 2021 Oct; 20(10):1127-1131. PubMed ID: 34636519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
    Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
    Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
    Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
    J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.
    Michelucci A; Manzo Margiotta F; Panduri S; Tonini A; Romanelli M; Morganti R; Janowska A; Dini V
    Dermatol Ther; 2022 Apr; 35(4):e15339. PubMed ID: 35088508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
    Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    J Dermatolog Treat; 2022 Aug; 33(5):2560-2564. PubMed ID: 35098859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
    Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
    J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab.
    Megna M; Fabbrocini G; Gallo L; Patrì A; Ruggiero A
    Curr Drug Saf; 2022; 17(4):390-392. PubMed ID: 35255793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab.
    Chiang CY; Tsai TF
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):301-306. PubMed ID: 33400156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.
    Hung YT; Lin YJ; Chiu HY; Huang YH
    Ther Adv Chronic Dis; 2021; 12():20406223211046685. PubMed ID: 34729147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    Dermatol Ther; 2021 Jan; 34(1):e14673. PubMed ID: 33314658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.